Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

3320 - Survival by sidedness of metastatic colorectal cancer (mCRC) treated with Epidermal Growth Factor Receptor Antibodies (EGFR-Ab) in the refractory setting: a population-based study of 1509 patients


09 Sep 2017


Poster display session


Cytotoxic Therapy;  Colon and Rectal Cancer


Eva Segelov


Annals of Oncology (2017) 28 (suppl_5): v158-v208. 10.1093/annonc/mdx393


E. Segelov1, C. Earle2, A.P. Venook3, R. Saskin4, L. Mofid4, S. Singh2

Author affiliations

  • 1 Medical Oncology, Monash University and Monash Health, 3168 - Melbourne/AU
  • 2 Medical Oncology, Sunnybrook Odette Cancer Center, Sunnybrook HSC, M4N 3M5 - Toronto/CA
  • 3 Medical Oncology And Translational Research, UCSF Helen Diller Family Comprehensive Cancer Center, 94115 - San Francisco/US
  • 4 Epidemiology, Institute for Clinical Evaluative Sciences, Toronto/CA


Abstract 3320


Sidedness of primary is an established prognostic factor in mCRC and recently has been shown to be an important predictive factor for patients (pts) treated with EGFR-Ab (always in combination with chemotherapy) in 1st and 2nd line settings. Limited data is available in 3rd line and beyond, where EGFR-Ab are used either as monotherapy or with chemotherapy. In Ontario, Canada, public funding of EGFR-Ab is restricted to chemorefractory disease. This study examines the impact of sidedness on overall survival (OS) in chemorefractory mCRC treated with EGFR-Ab monotherapy and combination.


This population-based retrospective cohort study used linked data from the Institute for Clinical Evaluative Sciences to evaluate mCRC pts treated in Ontario with EGFR-Ab from Jan 2006-Dec 2014. Over 99% of cases are captured via the Ontario Cancer Registry. The primary outcome was OS. Monotherapy v combination was compared by panitumumab (pani; funded only as monotherapy) v cetuximab (cet; funded only with chemotherapy) outcomes. Sidedness was determined by ICD-10 code as right (R; including transverse colon) or left (L).


Of 67117 CRC pts,1553 received EGFR-Ab for refractory mCRC (429 R, 1080 L, 44 unknown). 71% received pani. R were more commonly female, with significantly shorter time (months, m) from diagnosis to EGFR-Ab therapy (mean ± SD: 28.7 ± 18.3 v 32.8 ± 19.2; p 


This large population cohort demonstrates that R sidedness is significantly predictive for survival with EGFR-Ab in refractory mCRC, consistent with findings in earlier lines of therapy. The differences are particularly seen with monotherapy. L sided cancers appear to benefit equally from monotherapy as combination.

Clinical trial identification

Legal entity responsible for the study

Monash University




All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.